What is the potential utility of weekly taxol treatments for women with advanced uterine cancer?
The risk of recurrent or persistent uterine cancer for women with advanced disease is high. For this reason, the search for beneficial treatment approaches remains a priority in clinical research. In a recent issue of the journal Gynecologic Oncology, Dr. Maurie Markman and Dr. Jeffrey Fowler provide three case reports of women who received weekly infusions of low-dose Taxol after several other chemotherapy and/or radiation therapy regimens had failed to stop the progression of their disease. For these women, weekly Taxol treatments brought about improvement in both subjective symptoms and biological markers of cancer activity, i.e. CA-125 levels. Tumor response in these patients lasted for several months and afforded them satisfactory quality of life. Because this regimen is well-tolerated and less likely to produce significant side effects than most others, it may be a good choice for women who have diminished functional status due to previous therapy and/or disease status. The autho
